Skip to main content

Table 9 Incremental cost-effectiveness ratio of PEMF vs. standard treatment for acute scaphoid fractures for working patients only

From: Functional outcome and cost-effectiveness of pulsed electromagnetic fields in the treatment of acute scaphoid fractures: a cost-utility analysis

 

Costs*

QALY

ICER

Group A (Active)

€3305

0.8474

 

Group B (Placebo)

€2634

0.8415

 

Increment

€670

0.0059

113559

  1. *Costs are denoted in Euro.
  2. QALY, quality adjusted life year; ICER, incremental cost-effectiveness ratio.
Back to article page

BMC Musculoskeletal Disorders

ISSN: 1471-2474

Contact us